28 filings · most recent first
BIIB 8-K Filings
Biogen Reports Strong Q2 2026 Financial Results And Updates Guidance
Biogen Completes Acquisition Of Apellis Pharmaceuticals
Biogen Inc Announces Election Results From 2026 Annual Meeting Of Stockholders
Biogen Discloses Expected Acquired Rd Expenses For Q2 And Q3 2026
Biogen Reports Strong Q1 2026 Results And Announces Apellis Acquisition
Biogen Announces Agreement To Merge With Apellis Pharmaceuticals
Biogen Announces Departure Of Chief Legal Officer
Biogen Expects Q1 2026 Earnings Impact From Acquired Rd Expenses
Biogen Board Chair Transition
Biogen Reports Strong 2025 Financial Results And Provides 2026 Guidance
Biogen Inc Expects Q4 2025 Financial Impact From Acquired Rd
Biogen Inc Announces Issuance Of 175 Billion Senior Unsecured Notes
Biogen Inc Announces New Chief Accounting Officer And Executive Transitions
Biogen Announces Retirement Of Cfo Michael Mcdonnell And Appointment Of New Cfo
Biogen Inc Appoints Two New Directors To Board
Biogen Inc Enters Into New Credit Agreement And Terminates Existing One
Biogen Inc Adopts Exculpation Provision And Elects New Board Members
Biogen Reports Strong Q3 2025 Financials And Updates Guidance
Biogen Announces Estimated Third Quarter 2025 Expenses
Biogen Reports Strong Second Quarter 2025 Results And Raises Fullyear Guidance
Biogen Expects 46 Million Expense Impact On Q2 2025 Earnings
Biogen Annual Meeting Results Director Elections And Stockholder Approvals
Biogen Reports Strong Q1 2025 Results And Updates Fy 2025 Guidance
Biogen Reports Q4 And Fullyear 2024 Financial Results And Provides 2025 Guidance
Biogen Announces Q3 2024 Results And Raises Full Year Guidance
Biogen Reports Strong Q2 2024 Results And Raises Fullyear Guidance
Biogen Reports 1 Gaap Eps Growth And 8 Nongaap Eps Growth In Q1 2024
Biogen Reports 2023 Results And 2024 Guidance